ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Non-Small-Cell Lung Carcinoma

Adenocarcinoma trials near Nashville, TN, USA:

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC)....

Active, not recruiting
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Drug: Oxaliplatin
Drug: Fluorouracil

Phase 2

Jazz Pharmaceuticals
Jazz Pharmaceuticals

Nashville, Tennessee, United States and 20 other locations

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-...

Active, not recruiting
Pancreatic Ductal Adenocarcinoma
NRAS G12D
Drug: ELI-002 2P

Phase 1

Elicio Therapeutics
Elicio Therapeutics

Nashville, Tennessee, United States and 9 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

Nashville, Tennessee, United States and 203 other locations

A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: Trastuzumab
Drug: Paclitaxel

Phase 2, Phase 3

ALX Oncology

Nashville, Tennessee, United States and 83 other locations

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: Rilvegostomig

Phase 3

AstraZeneca
AstraZeneca

Nashville, Tennessee, United States and 195 other locations

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects with Unresectable, Advanced, And/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), tar...

Enrolling
Pancreatic Ductal Adenocarcinoma
Endometrial Cancer
Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D

Phase 1

Neogene Therapeutics

Nashville, Tennessee, United States and 11 other locations

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC (ESOGUARDBE2)

Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plu...

Enrolling
Esophageal Adenocarcinoma
Barretts Esophagus With Dysplasia
Diagnostic Test: Esophagogastroduodenoscopy
Device: EsoGuard (lab assay)
Lucid Diagnostics

Nashville, Tennessee, United States and 37 other locations

A Study of NT-175 in Adult Subjects with Unresectable, Advanced, And/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), tar...

Enrolling
Pancreatic Adenocarcinoma
Other Solid Tumors
Biological: Autologous, engineered T Cells targeting TP53 R175H

Phase 1

Neogene Therapeutics

Nashville, Tennessee, United States and 8 other locations

Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Drug: RMC-6236
Drug: nab-paclitaxel

Phase 1, Phase 2

Revolution Medicines
Revolution Medicines

Nashville, Tennessee, United States and 16 other locations

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)

in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuva...

Enrolling
Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer Metastatic
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 2, Phase 3

Panbela Therapeutics

Nashville, Tennessee, United States and 91 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems